Filing Flows › Aquestive Therapeutics (AQST) › Q3 2026
Aquestive Therapeutics (AQST) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Aquestive Therapeutics (AQST) reported revenue of $7.6M for the third quarter 2026 (Q3 2026), -41% from a year earlier and -45% from the quarter before. Operating margin was -191.5%, net loss $16.5M (218.3% of revenue).
Aquestive Therapeutics, Q3 2026: revenue $7.6M (-41% year over year), operating margin -191.5%, net loss $16.5M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.6M | -45% | -41% |
| Operating profit | −$14.5M | — | — |
| Net earnings | −$16.5M | — | — |
| Operating cash flow | −$7.0M | — | — |
What changed
Revenue was $7.6M in Q3 2026, down 41% year over year and down 45% from the previous quarter. Manufacture and supply revenue was the largest line at 88% of revenue. Manufacture and supply revenue lost $4.8M year over year (down 42%), 92% of the total change.
Operating costs exceeded revenue by $14.5M, an operating margin of -191.5%. Total costs fell 9% while revenue fell 41%. The quarter ended with a net loss of $16.5M, narrower than the previous quarter's $22.9M loss.
Operating cash flow was −$7.0M. Non-cash charges added back $156K of depreciation and $2.1M of share-based compensation. Working capital and other items added $7.2M. Capital expenditures of $584K exceeded it, leaving free cash flow of −$7.6M.
Questions
What was Aquestive Therapeutics' revenue in the third quarter 2026?
Aquestive Therapeutics (AQST) reported revenue of $7.6M for the third quarter 2026 (Q3 2026), -41% from a year earlier and -45% from the quarter before.
Was Aquestive Therapeutics profitable in the third quarter 2026?
Operating loss was $14.5M (-191.5% of revenue) and net loss $16.5M.